T-Cell Lymphoma Overview
Learn About T-Cell Lymphoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Dana-Farber Cancer Institute, Inc.
Eric Jacobsen is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Jacobsen and is rated as an Elite provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Jacobsen is currently accepting new patients.
Dana-Farber Cancer Institute, Inc.
Nicole Leboeuf is a Dermatologist in Boston, Massachusetts. Dr. Leboeuf and is rated as an Elite provider by MediFind in the treatment of T-Cell Lymphoma. Her top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Bullous Pemphigoid, and Lymphomatoid Papulosis. Dr. Leboeuf is currently accepting new patients.
Dana-Farber Cancer Institute, Inc.
David Fisher is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Fisher has been practicing medicine for over 36 years and is rated as an Elite provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), Non-Hodgkin Lymphoma, T-Cell Lymphoma, Bone Marrow Transplant, and Gastric Bypass. Dr. Fisher is currently accepting new patients.
Background: Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of the immune system caused by a mutation in the FAS gene. In ALPS, the body stores too many germ-fighting cells called lymphocytes. This can lead to an enlarged spleen and lymph nodes. Current treatments for ALPS can have many adverse effects. Better treatments for ALPS are needed.
Summary: This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in treating patients with cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with third-party natural killer cells, may induce changes in body'...